MovDisordV3, Main, Exploration, bibRecord, 003F35

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

Identifieur interne : 003F35 ( Main/Exploration ); précédent : 003F34; suivant : 003F36

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

Auteurs : Sebastian Paus [Allemagne] ; Hans Michael Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Gert Seeger [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-06.

RBID : ISTEX:0E477D90E1295A4CD3B48BCA7327C2D571D8AD20

Descripteurs français

Pascal (Inist)
- Agoniste, Homme, Jour, Parkinson maladie, Physiopathologie, Récepteur dopaminergique, Somnolence.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Activities of Daily Living, Aged, Agonist, Analysis of Variance, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Day, Disorders of Excessive Somnolence (chemically induced), Disorders of Excessive Somnolence (physiopathology), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine receptor, Drug Therapy, Combination, Epworth Sleepiness Scale, Female, Human, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pathophysiology, Questionnaires, Risk Factors, Sleep (drug effects), Somnolence, daytime sleepiness, dopamine agonists, sleep attacks.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists.
- chemically induced : Disorders of Excessive Somnolence.
- drug effects : Sleep.
- drug therapy : Parkinson Disease.
- physiopathology : Disorders of Excessive Somnolence.
- Activities of Daily Living, Aged, Analysis of Variance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Questionnaires, Risk Factors.

Abstract

To study the putative association of dopamine agonists with sleep attacks in patients with Parkinson's disease (PD) and their relation to daytime sleepiness, we performed a survey of 2,952 PD patients in two German counties. In 177 patients, sudden, unexpected, and irresistible sleep episodes while engaged in some activity were identified in a structured telephone interview. Ninety‐one of these patients denied the occurrence of appropriate warning signs. A total of 133 patients (75%) had an Epworth Sleepiness Scale (ESS) score >10; 65 (37%) >15. Thirty‐one patients (18%) had an ESS score ≤10 and yet experienced sleep attacks without warning signs. Thus, although a significant proportion of patients at risk for sleep attacks might be identified using the ESS, roughly 1% of the PD patient population seems to be at risk for sleep attacks without appropriate warning signs and without accompanying daytime sleepiness. Sleep attacks occurred with all dopamine agonists marketed in Germany (α‐dihydroergocryptine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropinirole), and no significant difference between ergot and nonergot drugs was evident. Levodopa (L‐dopa) monotherapy carried the lowest risk for sleep attacks (2.9%; 95% confidence interval [CI], 1.7–4.0%) followed by dopamine agonist monotherapy (5.3%; 95% CI, 1.5–9.2%) and combination of L‐dopa and a dopamine agonist (7.3%; 95% CI, 6.1–8.5%). Neither selegeline nor amantadine or entacapone appeared to influence the occurrence of sleep attacks. A high ESS score, intake of dopamine agonists, and duration of PD were the main influencing factors for the occurrence of sleep attacks. The odds ratio for dopamine agonist therapy was 2.9 compared to 1.9 with L‐dopa therapy and 1.05 for a 1‐year‐longer disease duration. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/0E477D90E1295A4CD3B48BCA7327C2D571D8AD20/fulltext/pdf

DOI: 10.1002/mds.10417

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease</title>
<author><name sortKey="Paus, Sebastian" sort="Paus, Sebastian" uniqKey="Paus S" first="Sebastian" last="Paus">Sebastian Paus</name>
</author>
<author><name sortKey="Brecht, Hans Michael" sort="Brecht, Hans Michael" uniqKey="Brecht H" first="Hans Michael" last="Brecht">Hans Michael Brecht</name>
</author>
<author><name sortKey="Koster, Jurgen" sort="Koster, Jurgen" uniqKey="Koster J" first="Jürgen" last="Köster">Jürgen Köster</name>
</author>
<author><name sortKey="Seeger, Gert" sort="Seeger, Gert" uniqKey="Seeger G" first="Gert" last="Seeger">Gert Seeger</name>
</author>
<author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
</author>
<author><name sortKey="Wullner, Ullrich" sort="Wullner, Ullrich" uniqKey="Wullner U" first="Ullrich" last="Wüllner">Ullrich Wüllner</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0E477D90E1295A4CD3B48BCA7327C2D571D8AD20</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10417</idno>
<idno type="url">https://api.istex.fr/document/0E477D90E1295A4CD3B48BCA7327C2D571D8AD20/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000470</idno>
<idno type="wicri:Area/Istex/Curation">000470</idno>
<idno type="wicri:Area/Istex/Checkpoint">002864</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Paus S:sleep:attacks:daytime</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12784269</idno>
<idno type="wicri:Area/PubMed/Corpus">003774</idno>
<idno type="wicri:Area/PubMed/Curation">003774</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003632</idno>
<idno type="wicri:Area/Ncbi/Merge">000A77</idno>
<idno type="wicri:Area/Ncbi/Curation">000A77</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A77</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Paus S:sleep:attacks:daytime</idno>
<idno type="wicri:Area/Main/Merge">005B57</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0381084</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002449</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000872</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002316</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Paus S:sleep:attacks:daytime</idno>
<idno type="wicri:Area/Main/Merge">005E62</idno>
<idno type="wicri:Area/Main/Curation">003F35</idno>
<idno type="wicri:Area/Main/Exploration">003F35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease</title>
<author><name sortKey="Paus, Sebastian" sort="Paus, Sebastian" uniqKey="Paus S" first="Sebastian" last="Paus">Sebastian Paus</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, University of Bonn, Bonn</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Bonn</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brecht, Hans Michael" sort="Brecht, Hans Michael" uniqKey="Brecht H" first="Hans Michael" last="Brecht">Hans Michael Brecht</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Boehringer Ingelheim Pharma KG, Ingelheim</wicri:regionArea>
<wicri:noRegion>Ingelheim</wicri:noRegion>
<wicri:noRegion>Ingelheim</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Koster, Jurgen" sort="Koster, Jurgen" uniqKey="Koster J" first="Jürgen" last="Köster">Jürgen Köster</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Boehringer Ingelheim Pharma KG, Ingelheim</wicri:regionArea>
<wicri:noRegion>Ingelheim</wicri:noRegion>
<wicri:noRegion>Ingelheim</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Seeger, Gert" sort="Seeger, Gert" uniqKey="Seeger G" first="Gert" last="Seeger">Gert Seeger</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Central Institute of Mental Health, Mannheim</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, University of Bonn, Bonn</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Bonn</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wullner, Ullrich" sort="Wullner, Ullrich" uniqKey="Wullner U" first="Ullrich" last="Wüllner">Ullrich Wüllner</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, University of Bonn, Bonn</wicri:regionArea>
<placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Cologne</region>
<settlement type="city">Bonn</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-06">2003-06</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="659">659</biblScope>
<biblScope unit="page" to="667">667</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">0E477D90E1295A4CD3B48BCA7327C2D571D8AD20</idno>
<idno type="DOI">10.1002/mds.10417</idno>
<idno type="ArticleID">MDS10417</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Agonist</term>
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Day</term>
<term>Disorders of Excessive Somnolence (chemically induced)</term>
<term>Disorders of Excessive Somnolence (physiopathology)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine receptor</term>
<term>Drug Therapy, Combination</term>
<term>Epworth Sleepiness Scale</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pathophysiology</term>
<term>Questionnaires</term>
<term>Risk Factors</term>
<term>Sleep (drug effects)</term>
<term>Somnolence</term>
<term>daytime sleepiness</term>
<term>dopamine agonists</term>
<term>sleep attacks</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sleep</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Homme</term>
<term>Jour</term>
<term>Parkinson maladie</term>
<term>Physiopathologie</term>
<term>Récepteur dopaminergique</term>
<term>Somnolence</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To study the putative association of dopamine agonists with sleep attacks in patients with Parkinson's disease (PD) and their relation to daytime sleepiness, we performed a survey of 2,952 PD patients in two German counties. In 177 patients, sudden, unexpected, and irresistible sleep episodes while engaged in some activity were identified in a structured telephone interview. Ninety‐one of these patients denied the occurrence of appropriate warning signs. A total of 133 patients (75%) had an Epworth Sleepiness Scale (ESS) score >10; 65 (37%) >15. Thirty‐one patients (18%) had an ESS score ≤10 and yet experienced sleep attacks without warning signs. Thus, although a significant proportion of patients at risk for sleep attacks might be identified using the ESS, roughly 1% of the PD patient population seems to be at risk for sleep attacks without appropriate warning signs and without accompanying daytime sleepiness. Sleep attacks occurred with all dopamine agonists marketed in Germany (α‐dihydroergocryptine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropinirole), and no significant difference between ergot and nonergot drugs was evident. Levodopa (L‐dopa) monotherapy carried the lowest risk for sleep attacks (2.9%; 95% confidence interval [CI], 1.7–4.0%) followed by dopamine agonist monotherapy (5.3%; 95% CI, 1.5–9.2%) and combination of L‐dopa and a dopamine agonist (7.3%; 95% CI, 6.1–8.5%). Neither selegeline nor amantadine or entacapone appeared to influence the occurrence of sleep attacks. A high ESS score, intake of dopamine agonists, and duration of PD were the main influencing factors for the occurrence of sleep attacks. The odds ratio for dopamine agonist therapy was 2.9 compared to 1.9 with L‐dopa therapy and 1.05 for a 1‐year‐longer disease duration. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Cologne</li>
<li>District de Karlsruhe</li>
<li>Rhénanie-du-Nord-Westphalie</li>
</region>
<settlement><li>Bonn</li>
<li>Mannheim</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Paus, Sebastian" sort="Paus, Sebastian" uniqKey="Paus S" first="Sebastian" last="Paus">Sebastian Paus</name>
</region>
<name sortKey="Brecht, Hans Michael" sort="Brecht, Hans Michael" uniqKey="Brecht H" first="Hans Michael" last="Brecht">Hans Michael Brecht</name>
<name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
<name sortKey="Koster, Jurgen" sort="Koster, Jurgen" uniqKey="Koster J" first="Jürgen" last="Köster">Jürgen Köster</name>
<name sortKey="Seeger, Gert" sort="Seeger, Gert" uniqKey="Seeger G" first="Gert" last="Seeger">Gert Seeger</name>
<name sortKey="Wullner, Ullrich" sort="Wullner, Ullrich" uniqKey="Wullner U" first="Ullrich" last="Wüllner">Ullrich Wüllner</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F35 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F35 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:0E477D90E1295A4CD3B48BCA7327C2D571D8AD20
   |texte=   Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.